Belzutifan showed antitumor activity with durable responses in participants with advanced pheochromocytoma or paraganglioma. (Funded by Merck Sharp and Dohme, a subsidiary of Merck [Rahway, NJ]; LITESPARK-015 ClinicalTrials.gov number, NCT04924075.).
PDF的下载单位、IP信息已删除
浮游
无极微光
yznfly
Zx_1993
xxfsx
欣喜的秋莲
ceeray23
tianzml0
子车茗
妩媚的海
VDC
你嵙这个期刊没买
sleep
Mic
pluto
寻道图强
彭于彦祖
风清扬
eric888
8R60d8
freyaaaaa
fei
chenqiumu
Maestro_S
皖公网安备34019202002308
